Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
出版年份 2023 全文链接
标题
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance
作者
关键词
-
出版物
JAMA Oncology
Volume 9, Issue 6, Pages 851
出版商
American Medical Association (AMA)
发表日期
2023-04-21
DOI
10.1001/jamaoncol.2023.0197
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study
- (2022) Junsik Park et al. GYNECOLOGIC ONCOLOGY
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
- (2022) Rebecca Kristeleit et al. LANCET ONCOLOGY
- Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study
- (2022) Junjie Huang et al. Cancers
- Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.
- (2022) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
- (2022) Ulka N. Vaishampayan et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy
- (2022) Jac A. Nickoloff MOLECULES
- 518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
- (2022) A.M. Oza et al. ANNALS OF ONCOLOGY
- Is there a role for secondary debulking in ovarian cancer? A review of the current literature
- (2022) Danielle Krause et al. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1 - and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer (026)
- (2022) Richard Penson et al. GYNECOLOGIC ONCOLOGY
- Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update
- (2022) William P. Tew et al. JOURNAL OF CLINICAL ONCOLOGY
- The current role of secondary cytoreductive surgery for recurrent ovarian cancer
- (2022) Eelco de Bree et al. Frontiers in Oncology
- Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2021) Stephanie Lheureux et al. LANCET
- Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
- (2021) K.N. Moore et al. ANNALS OF ONCOLOGY
- Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
- (2021) Sandro Pignata et al. LANCET ONCOLOGY
- Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
- (2021) Lukas Gorecki et al. Cancers
- T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review
- (2021) Jessica W. Y. Wu et al. Frontiers in Immunology
- The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
- (2021) Benoit You et al. CANCER TREATMENT REVIEWS
- Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer
- (2021) Haley A. Moss et al. GYNECOLOGIC ONCOLOGY
- Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)
- (2021) Stephanie Gaillard et al. GYNECOLOGIC ONCOLOGY
- Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
- (2021) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
- (2021) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study
- (2021) Kathleen N. Moore et al. CLINICAL CANCER RESEARCH
- Tumor treating fields: An emerging treatment modality for thoracic and abdominal cavity cancers
- (2021) Travis H. Jones et al. Translational Oncology
- Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer
- (2020) Carolyn E Haunschild et al. Future Oncology
- Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).
- (2020) Debra L. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
- (2020) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
- (2019) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-Drug Conjugates: A Comprehensive Review
- (2019) Puregmaa Khongorzul et al. MOLECULAR CANCER RESEARCH
- Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
- (2018) Belinda van Zyl et al. ENDOCRINE-RELATED CANCER
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
- (2018) Lauren C Peres et al. JNCI-Journal of the National Cancer Institute
- Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
- (2018) Matilda X. Lee et al. Journal of Gynecologic Oncology
- Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer
- (2017) Allison Gockley et al. OBSTETRICS AND GYNECOLOGY
- 5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease
- (2016) M. K. Wilson et al. ANNALS OF ONCOLOGY
- Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA–Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
- (2016) Christian Kurzeder et al. JOURNAL OF CLINICAL ONCOLOGY
- Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
- (2016) Åsa Fransson et al. Journal of Ovarian Research
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications
- (2015) Ignace B. Vergote et al. CANCER AND METASTASIS REVIEWS
- Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
- (2015) Andres M. Poveda et al. JOURNAL OF CLINICAL ONCOLOGY
- APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
- (2015) N Mohell et al. Cell Death & Disease
- Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
- (2014) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Lurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer
- (2012) A. Vidal et al. CLINICAL CANCER RESEARCH
- Evolution of platinum resistance in high-grade serous ovarian cancer
- (2011) Susanna L Cooke et al. LANCET ONCOLOGY
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
- (2011) D. G. Soares et al. MOLECULAR CANCER THERAPEUTICS
- Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
- (2010) D.L. Richardson et al. GYNECOLOGIC ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now